{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:40:51Z","timestamp":1791614451368,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006224","name":"Argonne National Laboratory","doi-asserted-by":"publisher","award":["DE-AC02-06CH11357"],"award-info":[{"award-number":["DE-AC02-06CH11357"]}],"id":[{"id":"10.13039\/100006224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008569","name":"Oklahoma Center for the Advancement of Science and Technology","doi-asserted-by":"publisher","award":["HR23-096"],"award-info":[{"award-number":["HR23-096"]}],"id":[{"id":"10.13039\/100008569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["75N93022C00035"],"award-info":[{"award-number":["75N93022C00035"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["5R01AI158775"],"award-info":[{"award-number":["5R01AI158775"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005825","name":"National Institute of Food and Agriculture","doi-asserted-by":"publisher","award":["2023-70432-39482"],"award-info":[{"award-number":["2023-70432-39482"]}],"id":[{"id":"10.13039\/100005825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005825","name":"National Institute of Food and Agriculture","doi-asserted-by":"publisher","award":["2023-67015-39096"],"award-info":[{"award-number":["2023-67015-39096"]}],"id":[{"id":"10.13039\/100005825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"US Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejmech.2023.116011","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T04:01:44Z","timestamp":1701748904000},"page":"116011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Structure-based design of SARS-CoV-2 papain-like protease inhibitors"],"prefix":"10.1016","volume":"264","author":[{"given":"Prakash","family":"Jadhav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Osipiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haozhou","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Tesar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Endres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jedrzejczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Joachimiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-4621","authenticated-orcid":false,"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.116011_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2023.116011_bib2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.116011_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/acs.accounts.2c00735","article-title":"SARS-CoV-2 main protease drug design, assay development, and drug resistance studies","volume":"56","author":"Tan","year":"2023","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2023.116011_bib4","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00044-022-02951-6","article-title":"The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations","volume":"31","author":"Joyce","year":"2022","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2023.116011_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00109-21","article-title":"SARS-CoV-2 antiviral therapy","volume":"34","author":"Tao","year":"2021","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2023.116011_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.116011_bib7","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.116011_bib8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for covid-19 - interim WHO solidarity trial results","volume":"384","author":"Consortium","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.116011_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","article-title":"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial","volume":"22","author":"Ader","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.116011_bib10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.116011_bib11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jiab247","article-title":"beta-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells","volume":"224","author":"Zhou","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.116011_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02404-21","article-title":"New perspectives on antimicrobial agents: molnupiravir and nirmatrelvir\/ritonavir for treatment of COVID-19","volume":"66","author":"Atmar","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.116011_bib13","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.116011_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115772","article-title":"Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: a comprehensive review","volume":"260","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116011_bib15","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41467-022-29104-y","article-title":"De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report","volume":"13","author":"Gandhi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.116011_bib16","article-title":"Nirmatrelvir resistance - de novo E166V\/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir\/ritonavir monotherapy leading to clinical and virological treatment failure - a case report","author":"Zuckerman","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.116011_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.24963","article-title":"Prevalence of low-frequency, antiviral resistance variants in SARS-CoV-2 isolates in ontario, Canada, 2020-2023","volume":"6","author":"Sjaarda","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejmech.2023.116011_bib18","first-page":"813","article-title":"Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2","volume":"4","author":"Hirotsu","year":"2023","journal-title":"M\u00e9d."},{"key":"10.1016\/j.ejmech.2023.116011_bib19","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.116011_bib20","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","article-title":"Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir","volume":"9","author":"Hu","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2023.116011_bib21","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2023.116011_bib22","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","article-title":"Progress and challenges in targeting the SARS-CoV-2 papain-like protease","volume":"65","author":"Tan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116011_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202200327","article-title":"SARS-CoV-2 papain-like protease: structure, function and inhibition","volume":"23","author":"Ullrich","year":"2022","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2023.116011_bib24","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1038\/s41467-023-38031-5","article-title":"Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin","volume":"14","author":"Wydorski","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.116011_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114572","article-title":"Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV\/SARS-CoV-2 papain-like protease inhibitors","volume":"240","author":"Valipour","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116011_bib26","doi-asserted-by":"crossref","first-page":"16119","DOI":"10.1073\/pnas.0805240105","article-title":"A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication","volume":"105","author":"Ratia","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.116011_bib27","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1021\/acscentsci.1c00519","article-title":"Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay","volume":"7","author":"Ma","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2023.116011_bib28","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","article-title":"Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity","volume":"65","author":"Shen","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116011_bib29","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41467-023-37254-w","article-title":"Potent and selective covalent inhibitors of the papain-like protease from SARS-CoV-2","volume":"14","author":"Sanders","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.116011_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.822785","article-title":"Potential inhibitors targeting papain-like protease of SARS-CoV-2: two birds with one stone","volume":"10","author":"Jiang","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2023.116011_bib31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/cmdc.202000223","article-title":"Drug development and medicinal chemistry efforts toward SARS-coronavirus and covid-19 therapeutics","volume":"15","author":"Ghosh","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.116011_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202212378","article-title":"Identification of cysteine 270 as a novel site for allosteric modulators of SARS-CoV-2 papain-like protease","volume":"61","author":"Hu","year":"2022","journal-title":"Angew. Chem."},{"key":"10.1016\/j.ejmech.2023.116011_bib33","article-title":"Structure-based design of potent peptidomimetic inhibitors covalently targeting SARS-CoV-2 papain-like protease","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.116011_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd4596","article-title":"Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design","volume":"6","author":"Rut","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2023.116011_bib35","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41467-020-20718-8","article-title":"The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery","volume":"12","author":"Fu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.116011_bib36","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41467-021-21060-3","article-title":"Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors","volume":"12","author":"Osipiuk","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.116011_bib37","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2023.116011_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"Baez-Santos","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.116011_bib39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1021\/acsptsci.1c00240","article-title":"Validation and invalidation of SARS-CoV-2 papain-like protease inhibitors","volume":"5","author":"Ma","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2023.116011_bib40","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00044-022-02903-0","article-title":"Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor","volume":"31","author":"Tan","year":"2022","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2023.116011_bib41","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nprot.2008.75","article-title":"Neutral red uptake assay for the estimation of cell viability\/cytotoxicity","volume":"3","author":"Repetto","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2023.116011_bib42","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1021\/acsinfecdis.1c00629","article-title":"Drug-repurposing screening identified tropifexor as a SARS-CoV-2 papain-like protease inhibitor","volume":"8","author":"Ma","year":"2022","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.116011_bib43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-1-4939-0354-2_7","article-title":"Protein production for structural genomics using E. coli expression","volume":"1140","author":"Makowska-Grzyska","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.116011_bib44","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1107\/S0907444906019949","article-title":"HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes","volume":"62","author":"Minor","year":"2006","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.ejmech.2023.116011_bib45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1107\/S0907444909042589","article-title":"Molecular replacement with MOLREP","volume":"66","author":"Vagin","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.ejmech.2023.116011_bib46","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.ejmech.2023.116011_bib47","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1107\/S0907444996012255","article-title":"Refinement of macromolecular structures by the maximum-likelihood method","volume":"53","author":"Murshudov","year":"1997","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.ejmech.2023.116011_bib48","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1107\/S0907444994003112","article-title":"Computational Project, the CCP4 suite: programs for protein crystallography","volume":"50","author":"Collaborative","year":"1994","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.ejmech.2023.116011_bib49","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.ejmech.2023.116011_bib50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity: all-atom structure validation for macromolecular crystallography","volume":"66","author":"Chen","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423009789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423009789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:10:56Z","timestamp":1778634656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423009789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":50,"alternative-id":["S0223523423009789"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.116011","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-based design of SARS-CoV-2 papain-like protease inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.116011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116011"}}